Henry Schein Medical announced its agreement with Cerebral Assessment Systems (CAS) to distribute Cognivue, the first computerized cognitive assessment screening device cleared by the Food and Drug Administration to detect early signs of dementia.

Cognivue helps practitioners to monitor current brain health and to monitor future reversible dementia treatments commonly caused by sleep disorders, infection, systemic illness, and mood disorders, enhancing the ability of patients and their families to plan for the future.

Cognivue will be on display at Henry Schein’s Medical Expo, which takes place on October 24-25 in Nashville, TN.

Cognivue is a fully automated solution that displays controlled visual stimuli on a computer screen, helping practitioners conduct a quantitative analysis of brain health to derive a composite score of overall brain functional integrity. The results are summarized on an easily interpreted report that is stored in the cloud, and provides a single quantitative score of brain health, enabling physicians to identify potential issues that can be addressed before problems get worse.

Created by Dr. Charles Duffy, based on his 20 years of neurophysiological and psychophysical research, Cognivue monitors and measures how the brain processes information, producing fast and accurate results of patient’s visual and motor capabilities. The test is customized based on the individual patient, calibrating levels of difficulty based on how well a patient’s brain is performing.

Cognivue will be on display at Henry Schein’s Medical Expo, which takes place on October 24-25 in Nashville, TN.

Visit Henry Schein for more information.

Home Daily Update Henry Schein Medical to distribute Cognivue, an automated screening device cleared to...